重组抗人CD19单抗(4G7) | Syd Labs PA007510.m1
体内实验级重组抗人CD28单克隆抗体，小鼠IgG1 Kappa（克隆号：CD28.2，Syd Labs货号：PA007477.m1），适用于体外和体内研究，纯度>95%。其不变区为小鼠Mouse IgG1 Kappa (mIgG1或m1)，可与重组小鼠IgG1同型对照抗体配套使用。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。
产品参数
| 货号 | PA007510.m1 |
|---|---|
| 产品名称 | 重组抗人CD19单抗(4G7) | Syd Labs PA007510.m1 |
| 英文名 | In vivo Grade Recombinant Anti-human CD19 Monoclonal Antibody, Mouse IgG1 Kappa (Clone: 4G7) |
| 供货商名称 | Syd Labs, Inc. |
| 品牌名 | Syd Labs |
| 别称 | B 淋巴细胞抗原 CD19，分化簇 19，B 淋巴细胞表面抗原 B4，T 细胞表面抗原 Leu-12，CVID3 |
| 概述 | Syd Labs提供重组小鼠IgG1同型对照抗体。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。 |
| 克隆号 | 4G7 |
| 同种型 | 小鼠 IgG1 kappa |
| 应用 | ELISA、流式细胞术、中和、功能测定，如生物分析PK和ADA测定，以及用于研究受人CD19蛋白影响的生物途径的测定。 |
| 免疫源 | 抗人CD19单克隆抗体（克隆：4G7）在哺乳动物细胞中产生 |
| 抗体形式 | 0.2 μM过滤溶液，1x PBS |
| 内毒素 | 根据 LAL 方法，≤1 EU每1mg 蛋白质 |
| 纯度 | >95%（在还原条件下通过SDS-PAGE测定） |
| 运输 | 体内实验级重组抗小鼠CD19单克隆抗体，小鼠IgG1 Kappa(克隆号4G7) 用冰袋运输。收到后，请立即将其存放在下面建议的温度下。 |
| 稳定性与存储 | 使用手动除霜冰箱并避免重复冻融循环。 自收到之日起 1 个月，保存在2 至 8°C。 自收到之日起12个月，保存在-20 至 -70°C。 |
| 注意事项 | PA007510.m1 Syd Labs提供重组小鼠IgG1同型对照抗体。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。 |
| 产品咨询 | Syd Labs在国内只通过代理商销售其产品，不做直销。终端用户咨询价格请联系Syd Labs中国代理商。 关于Syd Labs产品如果有任何技术或其它问题，欢迎随时联系Syd Labs国内市场推广合作伙伴：武汉多找找科技有限公司，企业微信：duozhaozhao2024 联系电话：18162581039（龙经理） |
| 应用详情 | ELISA、流式细胞术、中和、功能测定，如生物分析PK和ADA测定，以及用于研究受人CD28蛋白影响的生物途径的测定。 |
文献
抗人CD19单克隆抗体，体内实验级重组，小鼠IgG1 Kappa (克隆号4G7)（In vivo Grade Recombinant Anti-human CD19 Monoclonal Antibody, Mouse IgG1 Kappa (Clone: 4G7)，货号：PA007510.m1 Syd Labs）
4G7抗体能够结合人CD19蛋白。CD19是一种跨膜蛋白，表达于包括人浆细胞在内的所有B细胞系中。CD19在人B细胞中发挥两个主要作用：作为接头蛋白招募胞质信号蛋白至细胞膜，以及在CD19/CD21复合体中协同降低B细胞受体信号通路的激活阈值。CD19是B淋巴细胞发育和淋巴瘤诊断的生物标志物，也可作为白血病免疫治疗的靶点。
抗人CD19单抗(4G7)部分引用文献:
1. Multiplex Genome-Edited T-cell Manufacturing Platform for “Off-the-Shelf” Adoptive T-cell Immunotherapies
Poirot, L., et al. Cancer Res. 2015 Sep 15;75(18):3853-64. PMID: 26183927
“We provide proof of concept for the general application of this approach by manufacturing a TCR/CD52-deficient CD19 CAR T cell (dKO-CART19). …We demonstrate that this product does not mediate alloreactivity and that it can be selectively engrafted in the presence of alemtuzumab, while maintaining antitumor activity indistinguishable from standard CD19 CAR T cells in an orthotopic CD19+ lymphoma murine model. …CD19 CARs were cloned into a commercial lentiviral vector backbone downstream from an EF1-alpha promoter and concentrated lentiviral vectors were produced by Vectalys. …Furthermore, the antitumor activity of TCR-deficient T cells was not compromised, as CD19 CAR-transduced TCR-deficient T cells exhibited antitumor activity indistinguishable from standard CD19 CAR T cells in an orthotopic human CD19+ Raji-ffluc lymphoma model in NSG immunodeficient mice. …The same was true when using other cellular targets, that is, SupT1 cells engineered to express CD19 compared with control parental SupT1 cells (not shown).”
Poirot, L., et al. Cancer Res. 2015 Sep 15;75(18):3853-64. PMID: 26183927
“We provide proof of concept for the general application of this approach by manufacturing a TCR/CD52-deficient CD19 CAR T cell (dKO-CART19). …We demonstrate that this product does not mediate alloreactivity and that it can be selectively engrafted in the presence of alemtuzumab, while maintaining antitumor activity indistinguishable from standard CD19 CAR T cells in an orthotopic CD19+ lymphoma murine model. …CD19 CARs were cloned into a commercial lentiviral vector backbone downstream from an EF1-alpha promoter and concentrated lentiviral vectors were produced by Vectalys. …Furthermore, the antitumor activity of TCR-deficient T cells was not compromised, as CD19 CAR-transduced TCR-deficient T cells exhibited antitumor activity indistinguishable from standard CD19 CAR T cells in an orthotopic human CD19+ Raji-ffluc lymphoma model in NSG immunodeficient mice. …The same was true when using other cellular targets, that is, SupT1 cells engineered to express CD19 compared with control parental SupT1 cells (not shown).”
2. Pattern of CD14+ follicular dendritic cells and PD1+ T cells independently predicts time to transformation in follicular lymphoma
Smeltzer, J. P., et al. Clin Cancer Res. 2014 Jun 1;20(11):2862-72. PMID: 24727328
“To differentiate different PD1+ cells such as exhausted effector T cells and T follicular helper cells (TFH) cells, PD1+ cells were costained with CD3, CD19, CXCR5, and TIM3. …CD19+ cells were isolated from lymphoma samples by positive selection and cultured with FDCs at a ratio of 2.5:1. At 48 hours, viability of CD19+ cells was determined by the percentage of B cells that were negative by flow cytometry for Annexin V and propidium iodide. …To further analyze other markers of coexpression, flow cytometry was performed on follicular lymphoma samples with antibodies to CD3, CD19, and PD1. …The presence of FDC was associated with significant increase in viability of CD19+ cells (P = 0.003). B, sequential biopsies from diagnosis to transformation from two representative patient samples demonstrate a transition from PD1+ cells in the follicle to a diffuse pattern as patient nears transformation. …Cells were stained with fluorochrome-conjugated antibodies to human ICAM (R&D Systems; clone BBIG-l1), CD3 (clone HIT3a), CD19 (clone 4G7), PD1 (clone EH12.1), CD14 (clone M5E2), CD163 (clone GH1/61), CD21 (clone B-ly4), CD273 (clone M1H18), CD274 (clone M1H1), TIM3 (clone 344823), and CD23 (clone EBVCS-5; all obtained from BD Biosciences) and analyzed by flow cytometry and the data were analyzed using CellQuest software (Becton Dickinson).”
Smeltzer, J. P., et al. Clin Cancer Res. 2014 Jun 1;20(11):2862-72. PMID: 24727328
“To differentiate different PD1+ cells such as exhausted effector T cells and T follicular helper cells (TFH) cells, PD1+ cells were costained with CD3, CD19, CXCR5, and TIM3. …CD19+ cells were isolated from lymphoma samples by positive selection and cultured with FDCs at a ratio of 2.5:1. At 48 hours, viability of CD19+ cells was determined by the percentage of B cells that were negative by flow cytometry for Annexin V and propidium iodide. …To further analyze other markers of coexpression, flow cytometry was performed on follicular lymphoma samples with antibodies to CD3, CD19, and PD1. …The presence of FDC was associated with significant increase in viability of CD19+ cells (P = 0.003). B, sequential biopsies from diagnosis to transformation from two representative patient samples demonstrate a transition from PD1+ cells in the follicle to a diffuse pattern as patient nears transformation. …Cells were stained with fluorochrome-conjugated antibodies to human ICAM (R&D Systems; clone BBIG-l1), CD3 (clone HIT3a), CD19 (clone 4G7), PD1 (clone EH12.1), CD14 (clone M5E2), CD163 (clone GH1/61), CD21 (clone B-ly4), CD273 (clone M1H18), CD274 (clone M1H1), TIM3 (clone 344823), and CD23 (clone EBVCS-5; all obtained from BD Biosciences) and analyzed by flow cytometry and the data were analyzed using CellQuest software (Becton Dickinson).”
3. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia
Horton, H. M., et al. Cancer Res. 2008 Oct 1;68(19):8049-57. PMID: 18829563
“CD19 is a 95-kDa transmembrane glycoprotein of the immunoglobulin superfamily containing two extracellular immunoglobulin-like domains and an extensive cytoplasmic tail. …CD19 is an attractive target for cancers of lymphoid origin due to its high expression in most non-Hodgkin’s lymphomas (NHL) and many leukemias, including acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), and hairy cell leukemia (HCL; refs. 2, 3). …Thus, anti-CD19 antibodies may be efficacious against early B-cell malignancies such as ALL or other CD20-negative tumors, which are not amenable to treatment with rituximab, and as salvage regimens for patients failing rituximab. …CD19 has been a focus of immunotherapy development for over 20 years, and several CD19-specific antibodies have been evaluated for the treatment of B-lineage malignancies in vitro, in mouse models, and in clinical trials. …These clinical studies as well as trials with anti-CD19 immunoconjugates have validated CD19 as a target for B-cell malignancies, and the results with bispecific antibodies indicate that enhancing the engagement of immune effector functions may improve therapeutic efficacy.”
Horton, H. M., et al. Cancer Res. 2008 Oct 1;68(19):8049-57. PMID: 18829563
“CD19 is a 95-kDa transmembrane glycoprotein of the immunoglobulin superfamily containing two extracellular immunoglobulin-like domains and an extensive cytoplasmic tail. …CD19 is an attractive target for cancers of lymphoid origin due to its high expression in most non-Hodgkin’s lymphomas (NHL) and many leukemias, including acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), and hairy cell leukemia (HCL; refs. 2, 3). …Thus, anti-CD19 antibodies may be efficacious against early B-cell malignancies such as ALL or other CD20-negative tumors, which are not amenable to treatment with rituximab, and as salvage regimens for patients failing rituximab. …CD19 has been a focus of immunotherapy development for over 20 years, and several CD19-specific antibodies have been evaluated for the treatment of B-lineage malignancies in vitro, in mouse models, and in clinical trials. …These clinical studies as well as trials with anti-CD19 immunoconjugates have validated CD19 as a target for B-cell malignancies, and the results with bispecific antibodies indicate that enhancing the engagement of immune effector functions may improve therapeutic efficacy.”